While DCA exhibits sensitivity to PDK2 and holds promise for augmenting cisplatin sensitivity, its clinical translation is impeded by its limited efficacy in suppressing tumor growth and the associated systemic toxicity. This evidence concerns the gene PDK2 and neoplasm.